numares’ Novel GFR Equation Allows Accurate Assessment of Renal Insufficiency in Proof of Concept
Leading NMR diagnostics company numares recently published data showing that its novel, multi-marker approach to assess kidney function allowed for a more precise estimation of glomerular filtration rate (GFR) by a simple serum test. Named GFRNMR , the test provided metabolic characterization of renal dysfunction, by evaluating a group of metabolites. This “metabolite constellation” was comprised of myo-inositol, dimethylsulfone, valine, and creatinine, independently from age and sex. The test holds the potential for an improved assessment of kidney function, and deeper insights into kidney pathophysiology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210225005061/en/
numares uses “metabolite constellations”: a set of combined metabolic biomarkers evaluated by AI, to assess kidney function with serum-based GFRNMR test. (Graphic: Business Wire)
In this proof-of-concept study, published in the peer-reviewed journal Diagnostics1 , numares showed that a combination of multiple renal biomarkers, all with pathophysiological relevance, may overcome the diagnostic limitations of existing methods used to estimate GFR. This is a measure of kidney function used for assessment of metabolic renal dysfunction associated with chronic kidney disease.2
GFRNMR is based on numares’ metabolomics approach: a combination of multiple metabolites, forming a metabolite constellation, analyzed by advanced nuclear magnetic resonance (NMR) spectroscopy and evaluated by numares’ proprietary, AI-driven AXINON® diagnostic software. Following a targeted metabolomics approach, numares identified and combined the metabolites myo-inositol, dimethylsulfone, valine, and creatinine into a unique metabolite constellation, developing an algorithm which enables improved assessment of kidney function by a simple serum test.
The multi-marker algorithm was trained with 95 bio-banked serum samples and tested in 189 independent samples originated from Lyon/France, Gothenburg/Sweden, and Berlin/ Germany. The results were compelling: GFRNMR correlated better with measured GFR. Overall percentages of GFRNMR values matched, or more frequently exceeded those for commonly used, recommended eGFR equations.
“The outcome of this proof of concept surpassed equations used to estimate GFR which are recommended by KDIGO and commonly used to assess kidney function,” says Winton Gibbons, President – US and co-Chief Executive Officer of numares. “Subsequent to this proof of concept, we have been able to further refine our metabolite-based modeling, using a much broader set of samples. This newer model resulted in yet more promising data in a US-based validation study. In total, the GFRNMR approach is now validated in clinical studies with ~1,500 patient samples, and numares plans to submit the GFRNMR test for FDA Clearance in the first half 2021.“
1 Full article: Ehrich, J., et al., Serum myo-inositol, dimethyl sulfone, and valine in combination with creatinine allow accurate assessment of renal insufficiency. Diagnostics 2021, 11(2), 234; available at https://www.mdpi.com/2075-4418/11/2/234/htm
2 Current diagnostics in kidney function assessment:
Fifteen percent of U.S. adults (37 million people) are estimated to have chronic kidney disease (CKD)*. Evaluation of renal dysfunction includes estimation of glomerular filtration rate (eGFR) as the initial step and subsequent laboratory testing. Existing methods for eGFR with endogenous markers still present important drawbacks. As a result several eGFR equations have been developed but were commonly found to be insufficient to assess patients’ complex renal dysfunction and complications according to the stages of CKD.
* Source: https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html
About numares
numares AG, based in Regensburg, Germany, is a fast-growing innovative diagnostics company that applies machine learning to metabolomics data to develop advanced analytical tests for high-throughput use in clinical diagnostics. The AXINON® System employs advanced nuclear magnetic resonance (NMR) spectroscopy to evaluate metabolic constellations. Magnetic Group Signaling (MGS® ) is a proprietary technology that enables NMR for highly standardized and rapid throughput testing. Metabolic tests stand as an important pillar in precision medicine to address unmet needs in cardiovascular, kidney, liver, and neurological diseases. You will find more information at https://www.numares.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210225005061/en/
Contact information
For further information please contact:
numares
Christiane Proll
Tel.: +49 941 280 949-14
E-Mail: christiane.proll@numares.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Global Tourism Surging Ahead of Economic Growth, With Visits to Hit 30 Billion by 20344.7.2025 02:00:00 EEST | Press release
The World Economic Forum has today published a new report forecasting that the travel and tourism industry is projected to serve 30 billion tourist trips by 2034. Travel and Tourism at a Turning Point: Principles for Transformative Growth, produced in collaboration with Kearney and the Ministry of Tourism Saudi Arabia, reveals a projected $16 trillion contribution to global GDP by the same year—representing more than 11% of the total world economy, according to World Travel & Tourism Council estimates. The report also found that the sector is expanding 1.5 times faster than the global economy, generating significant commercial opportunities as long as the mounting challenges of climate change, labour shortages and infrastructure gaps are addressed. Inbound and outbound trips increasing fast Asia is on track to become the world’s fastest-growing tourism economy, with the direct travel and tourism GDP contribution expected to exceed 7% across the region by 2034. Notably, India and China
The 2025-2026 World Branding Awards Animalis Edition Honouring Leading Pet and Animal Brands Globally3.7.2025 22:00:00 EEST | Press release
The 2025-2026 World Branding Awards Animalis Edition marked its fifth instalment, bringing together leading pet and animal brands from all around the world. These brands were celebrated for their outstanding achievements, earning recognition as National, Regional, and Global Winners. The awards ceremony, held at Vienna's prestigious Hofburg Palace, welcomed winners across diverse categories, including pet food, retail, wellness, pet exhibitions, and aquatic products. Mounia Berrada-Gouzi expertly hosted the evening, which culminated in a grand celebration of brand excellence. “The Animalis Edition of the World Branding Awards recognises brands that have achieved the highest distinction—genuine recognition in the hearts and minds of consumers. Tonight, we honour those whose names resonate globally, whose values inspire loyalty, and whose presence defines excellence in the pet and animal industry,” said Richard Rowles, Chairman of the World Branding Forum. Out of over 950 brands nominate
Venture Global Announces 20-Year Sales and Purchase Agreement with PETRONAS3.7.2025 15:59:00 EEST | Press release
Today, Venture Global, Inc. (NYSE: VG) announced the execution of a new 20-year Sales and Purchase Agreement (SPA) with PETRONAS LNG Ltd. (PLL), a subsidiary of the Malaysian state-owned oil and gas company, PETRONAS. Under the terms of the SPA, PETRONAS will purchase 1 million tonnes per annum (MTPA) of liquefied natural gas (LNG) from Venture Global’s third facility, CP2 LNG, for 20 years. This builds upon Venture Global’s existing agreement with PETRONAS for 1 MTPA of LNG supply from Plaquemines LNG. PETRONAS, a world-class partner in the LNG industry, joins other CP2 LNG customers in Europe, Asia and the rest of the world in a strategically important project to global energy supply and security. To date, approximately 10.75 MTPA of the 14.4 MTPA nameplate capacity for CP2 Phase One has been sold. About Venture Global Venture Global is a long-term, low-cost provider of U.S. LNG sourced from resource rich North American natural gas basins. Venture Global’s business includes assets ac
Frost & Sullivan Recognizes Novotech as 2025 Global Biotech CRO Company of the Year3.7.2025 15:05:00 EEST | Press release
In recognition of its innovation, client-focused delivery, and global impact, Novotech has been awarded the 2025 Global Biotechnology Contract Research Organization (CRO) Company of the Year by Frost & Sullivan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250703950144/en/ Novotech Wins Global CRO Award Novotech is a globally recognized full-service clinical CRO and scientific advisory firm, trusted by biotech and small- to mid-sized pharmaceutical companies to advance their drug development programs at every phase. With a global footprint spanning Asia-Pacific, North America, and Europe, Novotech supports over 5,000 clinical trial sites and a distributed team of experts delivering seamless, end-to-end solutions across geographies. “Novotech is redefining biotech-focused clinical research through AI-driven innovation, global expansion, and a client-embedded partnership model. With a clear vision to be the CRO of choice for
Tinnitus Research: Novel Compound AC102 Makes Constant Ear Noise Disappear in Preclinical Model3.7.2025 13:02:00 EEST | Press release
The novel compound AC102 almost completely reversed tinnitus in a preclinical model after a single dose. At the same time, the damaged connections between the auditory nerve and inner ear sensory cells were restored. These findings were recently published in the prestigious International Journal of Molecular Sciences in a joint study conducted by Erlangen University Hospital and Berlin-based drug developer AudioCure. As there is currently no causal treatment for tinnitus, there is a high medical need. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702168211/en/ In 10-20% of tinnitus cases, the noise in the ear is so severe that it significantly impairs the quality of life of those affected. (Source: AI-generated) In the current study, AC102 was administered to the middle ear of one experimental group after acoustic trauma, while a second group received a placebo. Although both groups initially showed signs of tinnitus, th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom